Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

Jaundice Clinical Trial

Official title:

Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00383318
• Other study ID #: PDX 06-001
• Status: Completed
• Phase: N/A
• First received: October 2, 2006
• Last updated: January 24, 2008
• Start date: September 2006
• Est. completion date: December 2007

Study information

• Verified date: January 2008
• Source: Mednax Center for Research, Education and Quality
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia to patients who never developed a significant bilirubin level.

Description:

The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia (serum bilirubin level in the "high risk zone of greater than the 95th percentile based on the Bhutani nomogram) to patients who never developed significant hyperbilirubinemia (bilirubin level in "low risk zone of less than the 40th percentile" on Bhutani nomogram and who did not require any treatment for hyperbilirubinemia). Our primary goal is to determine if common gene mutations occur at a greater frequency in patients with severe hyperbilirubinemia than in neonates without significant hyperbilirubinemia.

The gene mutations we will test for are:

• Glucose-6-phosphate Dehydrogenase Deficiency [G6PD] gene mutations

• African A- mutation (G202A;A376G)

• The common Mediterranean mutation (C563T)

• Two common Chinese mutations (G1376T and G1388A)

• UGT1A1 polymorphism. The UGT1A1 gene polymorphisms refer to those genetic defects found to be associated with Gilbert's Syndrome, including a promoter defect (T-3263G) that disrupts a transcription regulatory site, the TA repeats promoter polymorphism, and four mutations within the coding region (G211A, C686A, C1091T, and T1456G).

• Gene polymorphism for the organic anion transporting protein (OATP-2)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 450
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A to 6 Days

Eligibility

Inclusion Criteria:

Case

• Documentation of informed consent.

• Gestational age greater than or equal to 37 weeks.

• Birth weight greater than or equal to 2000 grams.

• At least one serum bilirubin level that is greater than the 95th percentile ("high risk zone") based on the Bhutani nomogram(1), for the case population.

• Age at enrollment less than 7 days or less than or equal to 168 hours.

• No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia, or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies).

• Ability to follow subjects transferred to another facility for outcome data.

Control

• Documentation of informed consent.

• Gestational age greater than or equal to 37 weeks.

• Birth weight greater than or equal to 2000 grams.

• At least one estimate of serum bilirubin. Bilirubin level estimated to be less than the 40th percentile ("low risk zone") based on the Bhutani nomogram. While a serum bilirubin in the low risk zone is the preferred method for assessing the bilirubin level, many pediatricians use transcutaneous measure of bilirubin as a screening tool for identifying "low risk" patients. For this reason, we will allow controls to be identified using transcutaneous measurements and collect serum bilirubin levels only as clinically indicated.

• Age at enrollment less than 7 days or less than or equal to 168 hours.

• No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies).

• Ability to follow subjects transferred to another facility for outcome data.

Exclusion Criteria:

Case and Control

• Gestational age less than 37 weeks.

• Birth weight less than 2000 grams.

• Older than 7 days of age or 168 hours.

• Any major congenital anomalies.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Hyperbilirubinemia
• Jaundice

Intervention

Procedure:
• Gene mutation sample

Locations

Country	Name	City	State
United States	Greenville Medical Center	Greenville	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Mednax Center for Research, Education and Quality

Country where clinical trial is conducted

United States, 

References & Publications (4)

Bhutani VK, Johnson LH, Jeffrey Maisels M, Newman TB, Phibbs C, Stark AR, Yeargin-Allsopp M. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004 Oct;24(10):650-62. Review. — View Citation

Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glicken S, Maisels MJ, Lau J; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004 Jul;114(1):e130-53. Review. — View Citation

Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. 2002 Apr;140(4):396-403. — View Citation

Watchko JF. Vigintiphobia revisited. Pediatrics. 2005 Jun;115(6):1747-53. Review. — View Citation